Medtronic presents data on MiniMed670G, Sugar.IQ and other diabetes offerings
Medtronic (NYSE:MDT) released it’s biggest news prior to the ADA, launching its MiniMed 670G hybrid closed loop system, but still had a number of presentations related to it’s diabetes tech offerings.
The Fridley, Minn.-based company presented a number of studies on its newly launched MiniMed 670G, as well as its Sugar.IQ cognitive app, which was developed through a joint effort with IBM (NYSE:IBM) Watson Health’s pattern recognition software.
Here’s what Medtronic presented at the conference:
-
Results at 1 year of MiniMed 670G confirm device safety, report sustained glycemia improvements
-
Novel composite metric analysis of MiniMed 670G pivotal trial shows reduced hypoglycemia intensity
-
MiniMed 670G pivotal trial analysis investigates effect of pre-meal insulin bolus
-
Unique insights from a retrospective analysis of Sugar.IQ data
-
Improved glucose control demonstrated in patients receiving Diabeter model of comprehensive care